Oral selective estrogen receptor degraders Agent Status and key trial data What to watch Elacestrant (Orserdu) Approved in 2023 as the first oral SERD in ESR1-mutant metastatic breast cancer via...

Health care consulting and technology organization awarded 2025 All-Star Awards to nine Prime employees

Designation demonstrates highest level of commitment to quality health care

Designation demonstrates highest level of commitment to quality health care.